Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer

Sponsor
Santa Chiara Hospital
Study ID
NCT06783127
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
MALE
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Olaparib — DRUG
    Olaparib given according the clinical practice to BRCA positive mCRPC patients

Study Details

This is an observational, retrospective/prospective, multicenter study designed to define, overall survival, clinical outcomes and predictive/prognostic factors of a consecutive population of mCRPC patients treated with olaparib in clinical practice.

Key Dates

Start date
Jan 1, 2023
Status verified
Feb 2025
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
3,000 participants (estimated)

Arms

  • Arm: mCRPC treated with olaparib
    mCRPC patients who receive olaparib in daily clinical practice

Primary Outcome Measure

disease control [ Time Frame: From the date of treatment start until the date of last follow-up or date of death from any cause, whichever came first, assessed up to 120 months ]

Central Contacts

Related Studies